ARTICLE | Company News
Concert Pharmaceuticals, National Multiple Sclerosis Society neurology news
March 12, 2012 7:00 AM UTC
The society's Fast Forward LLC not-for-profit subsidiary committed up to $750,000 to fund preclinical development of Concert's spasticity and pain candidate C-21191. The product is a deuterium-modifi...